Financial Performance - Operating revenue for Q1 2023 increased by 50.22% to ¥51,992,826.56 compared to Q1 2022[9] - Net profit attributable to shareholders improved by 42.10%, reaching a loss of ¥1,531,212.96 in Q1 2023 compared to a loss of ¥2,644,614.23 in Q1 2022[9] - The net profit for the reporting period was -5,712,537.96, compared to -303,437.77 in the same period last year, indicating a significant decline in profitability[16] - The company reported a comprehensive income total of -5,688,663.19 for the period, compared to -303,437.77 in the previous year[16] - The net loss for Q1 2023 was ¥3,757,096.48, an improvement from a net loss of ¥5,732,719.17 in Q1 2022[44] - The net profit for Q1 2023 was ¥4,014,569.93, representing a 37.4% increase from ¥2,921,869.03 in Q1 2022[46] Assets and Liabilities - Total assets as of March 31, 2023, decreased by 4.79% to ¥574,690,257.25 compared to the end of 2022[9] - The company’s asset-liability ratio decreased to 14.69% in Q1 2023 from 18.11% at the end of 2022[9] - The total assets at the end of the reporting period amounted to 602,268,634.53, an increase from 480,068,803.10 in the previous year, representing a growth of approximately 25.5%[16] - The total liabilities increased from 108,089,664.84 to 109,300,685.24, showing a slight rise of about 1.1%[16] - The total liabilities decreased to CNY 84,421,535.35 from CNY 109,300,685.24, a decrease of approximately 22.77%[37] - The company's total equity decreased to CNY 490,268,721.90 from CNY 494,292,044.20, reflecting a decline of about 0.46%[37] Cash Flow - Cash flow from operating activities decreased by 67.40%, resulting in a net outflow of ¥32,456,881.66 in Q1 2023[9] - The cash flow from operating activities for Q1 2023 was negative at -¥32,456,881.66, worsening from -¥19,388,807.48 in Q1 2022[50] - Cash inflow from investment activities in Q1 2023 was ¥120,499,024.66, a substantial increase from ¥60,103,561.64 in Q1 2022[50] - The company reported a cash outflow from investment activities of ¥131,381,959.97 in Q1 2023, compared to ¥63,120,359.46 in Q1 2022, indicating increased investment activity[50] - The net cash flow from financing activities in Q1 2023 was -¥1,000,344.07, a decrease from a positive cash flow of ¥645,438.97 in Q1 2022[51] Investments and Costs - The company reported a 71.54% increase in operating costs due to higher sales and lower gross margins on certain products[11] - Investment income rose by 108.69% in Q1 2023, attributed to gains from the acquisition of Jinan Haisen Analytical Instrument Co., Ltd.[11] - The company plans to enhance market investment in high-efficiency chromatographic instruments, contributing to revenue growth[11] - Research and development expenses for Q1 2023 were ¥11,300,041.16, showing a marginal increase from ¥11,251,860.51 in Q1 2022[44] - Research and development expenses for Q1 2023 amounted to ¥3,683,078.07, slightly up from ¥3,384,143.08 in Q1 2022, indicating continued investment in innovation[46] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 2,281, with a total share capital of 81,435,280[19] - The largest shareholder, Wang Zhigang, holds 15,616,920 shares, representing 19.18% of the total shares[21] - The total equity attributable to shareholders of the parent company was 488,397,705.22, up from 354,562,886.53 year-on-year, reflecting a growth of about 37.6%[16] Other Information - The company has no significant litigation or arbitration matters during the reporting period[26] - The company has fulfilled its commitments regarding employee incentive measures and other major transactions in a timely manner[26] - The deferred tax assets decreased from 17,599,483.83 to 16,275,388.92, a decline of approximately 7.5%[16] - The company approved a leasing agreement with a related party for an annual rent of CNY 51,100 for a 400 square meter facility[28] - The company plans to increase its investment in its associate companies, including Jinan Haisen Analysis Instrument Co., Ltd. and White Xiaobai Future Technology (Beijing) Co., Ltd.[29]

Financial Performance - The company's operating revenue for 2022 was RMB 287,368,494.44, representing a 16.34% increase from RMB 247,007,059.69 in 2021[27]. - The net profit attributable to shareholders for 2022 was RMB 44,434,615.38, a decrease of 16.76% compared to RMB 53,379,468.44 in 2021[27]. - The total assets at the end of 2022 amounted to RMB 602,268,634.53, reflecting a 25.45% increase from RMB 480,068,803.10 in 2021[29]. - The total liabilities decreased by 6.81% to RMB 108,089,664.84 in 2022 from RMB 115,991,537.25 in 2021[29]. - The net asset attributable to shareholders increased by 37.75% to RMB 488,397,705.22 in 2022 from RMB 354,562,886.53 in 2021[29]. - The cash flow from operating activities for 2022 was RMB 70,044,668.58, a 66.17% increase from RMB 42,152,471.97 in 2021[31]. - The gross profit margin for 2022 was 69.26%, up from 66.88% in 2021[27]. - The basic earnings per share for 2022 was RMB 0.60, down 20.00% from RMB 0.75 in 2021[27]. - The current ratio improved by 77.51% to 3.71 in 2022 from 2.09 in 2021[29]. - The interest coverage ratio was 29.38 in 2022, down from 39.93 in 2021[29]. - Operating revenue growth rate for 2022 was 16.34%, down from 17.59% in 2021 and up from 6.39% in 2020[33]. - Net profit growth rate for 2022 decreased by 23.18%, while it increased by 76.67% in 2021 and 19.10% in 2020[33]. - The company's total operating revenue for 2022 was CNY 287,368,494.44, with a variance of 0.00% from the preliminary report[34]. - Net profit attributable to shareholders was CNY 44,434,615.38, showing a slight decrease of 0.31% from the preliminary report[34]. Research and Development - Research and development expenses amounted to RMB 44,844,900, representing 15.61% of total revenue during the reporting period[5]. - The company has maintained a research and development investment ratio exceeding 13% of revenue for five consecutive years, reflecting its commitment to innovation[11]. - The company obtained 5 new invention patents and 6 utility model patents, bringing the total to 29 invention patents and 84 utility model patents by the end of the reporting period[5]. - The company participated in drafting and revising 4 national standards and 3 industry standards, enhancing its technical strength in the field of liquid chemical products[5]. - The company is expanding its product offerings in the chromatography field, focusing on high-performance liquid chromatography and gas chromatography-ion mobility spectrometry[44]. - The company plans to enhance its product matrix and market presence, focusing on high-efficiency liquid chromatography and gas chromatography-IMS products[55]. - The company is developing the K2025 Pro project, which aims to enhance the performance and reliability of liquid chromatography instruments[100]. - The company is focused on increasing automation and reliability in its products, aiming to reach industry-leading levels in detection speed and accuracy[102]. - The company is exploring new applications for its technologies, which are expected to have a significant positive impact on future growth[101]. - The company is actively pursuing new technologies and products to enhance its market position and competitiveness[100]. Market and Competition - The company faces risks related to market competition, particularly in high-end scientific instruments where domestic brands have low market share compared to foreign competitors[12]. - Seasonal fluctuations in sales are expected, with lower business volume in the first half of the year due to the procurement cycle of government and research institutions[12]. - The scientific instrument industry is characterized by high technical barriers and a wide range of applications across various sectors, including food safety and environmental monitoring[59]. - The company operates in a market with significant potential for domestic substitution of imported high-end scientific instruments[61]. - The trend of domestic instruments replacing imported ones is becoming more pronounced due to advancements in technology and government support[11]. - The global scientific instrument market is projected to reach USD 102 billion by 2026, a 48% increase from 2021[9]. Corporate Governance and Structure - The company has 13 wholly-owned subsidiaries and 4 affiliated companies, indicating a strategy of multi-brand and multi-product development[11]. - The actual controller's shareholding decreased to 19.18% after the public issuance of shares, which may affect decision-making efficiency in significant matters[11]. - The company has established a competitive salary and benefits system, with costs for employee compensation increasing year by year[190]. - The company has implemented a stock option incentive plan, with the exercise price adjusted to 6.30 yuan per share[188]. - The company has established new corporate governance systems during the year[200]. - The company has engaged in external guarantees, although specific amounts and details were not disclosed[129]. - The company has established a continuous communication channel with its auditor, ensuring compliance and oversight during the audit process[6]. Financial Management and Investments - The company raised a total of ¥108,800,000 from the public offering, with funds allocated for upgrading the production base and supplementing working capital[160]. - The company has utilized ¥33,778,368 of the raised funds during the reporting period[162]. - The remaining balance of the raised funds in the account is ¥75,159,657.29[163]. - The company plans to use up to RMB 60,000,000.00 of idle raised funds for cash management, investing in low-risk financial products[167]. - The company holds a total of 7,989,967.23 RMB in convertible bonds, with a conversion price set at 0.533 GBP per share if certain conditions are met[169]. - The company completed the acquisition of 75% of the partnership interest in Haineng Jifu, resulting in a 100% ownership stake[169]. - The total amount of loans provided by banks and non-bank financial institutions reached CNY 24,000,000.00 during the reporting period[174]. - The interest rate for the loans provided was consistently set at 3.85%[175]. Social Responsibility - The company has donated a total of CNY 200,000 to support pandemic prevention efforts in 2022[8]. - The company has been actively involved in educational funding, contributing a total of CNY 177,000 to various educational foundations since 2011[8]. Risks and Uncertainties - The company faces a risk of market competition, with over 70% of large scientific instruments in China being imported, particularly in high-end segments[124]. - There are no significant uncertainties affecting the company during the reporting period[121]. - The company has no significant litigation or arbitration matters during the reporting period, indicating a stable legal environment[129]. Employee and Management Changes - The total number of management personnel decreased from 35 to 27, reflecting a reduction of 22.9%[189]. - The company had a total of 505 employees at the end of the reporting period, an increase of 25 employees from the beginning of the period[189]. - The number of technical personnel increased by 18.6% from 153 to 171 during the reporting period[189]. - The company has implemented a responsibility accountability system for major errors in the annual report[200].

Financial Performance - The company achieved operating revenue of CNY 287.37 million, a year-on-year increase of 16.34%[2] - Net profit attributable to shareholders decreased by 16.50% to CNY 44.57 million[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 35.16 million, down 0.88% year-on-year[2] - Basic earnings per share decreased by 20.00% to CNY 0.60[2] Assets and Equity - Total assets at the end of the reporting period reached CNY 602.38 million, an increase of 25.48% compared to the beginning of the period[2] - Shareholders' equity attributable to the company increased by 37.83% to CNY 488.70 million[2] Investment and R&D - The company focused on increasing market share and enhancing product quality through increased R&D and production investments[4] - The decline in net profit was partly due to increased investment losses from early-stage R&D projects and market introduction phases[5] - The company raised funds through a public offering of shares to unspecified qualified investors, contributing to the increase in total assets and equity[6] Financial Reporting - Investors are advised that the financial data presented is preliminary and unaudited, and final figures will be disclosed in the annual report[7]

证券代码：430476 证券简称：海能技术 公告编号：2022-132 海能未来技术集团股份有限公司 关于接待机构投资者调研情况的公告 | --- | |------------------------------------------------------------------------| | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | 带法律责任。 | 海能未来技术集团股份有限公司（以下简称"公司"）于 2022 年 11 月 21 日接待了 18 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 11 月 21 日 调研地点：山东省德州市临邑县花园东大街 16 号（山东海能科学仪器有限 公司） 调研形式：现场调研 调研机构：国金证券、中金公司、上海证券、硕腾基金、巨杉资产、德邦资 管、怀澄投资、博裕资本、启峰资本、中域资产、通用投资、上投摩根、敦和资 产、高信百诺、重阳资本、博鸿资产、久久联创投资、五地投资 上市公司接待人员：董事长王志刚先生；副董 ...